ResMed| (RMD) Stock Price, Fundamentals & Analysis
Price
222.3 USD
+0.15%
Price history
Over the past year RMD traded between 182.82 USD and 283.28 USD, closing at 222.3 USD on Sep 24, 2026.
Key statistics
| Market cap | 32.07B USD |
|---|---|
| P/E ratio (TTM) | 21.3 |
| Forward P/E | 16.8 |
| EPS (TTM) | 10.42 USD |
| Dividend yield | 1.19% |
| Annual dividend | 2.64 USD |
| Ex-dividend date | Aug 20, 2026 |
| Payout ratio | 23% |
| 52-week range | 180.27 – 284.87 |
| 52-week change | -19% |
| Beta | 0.77 |
| Price / book | 4.87 |
| Revenue (TTM) | 5.65B USD |
| Revenue growth (YoY) | 8.6% |
| Gross margin | 61.6% |
| Operating margin | 30.9% |
| Profit margin | 26.9% |
| Return on equity | 24.3% |
| Debt / equity | 12.5 |
| Volume | 1,358,991 |
| Average volume | 1,469,520 |
| Next earnings | Oct 29, 2026 |
| Exchange | NYSE |
Profile
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Employees
- 11,370
- Headquarters
- San Diego, United States
- Website
- resmed.com
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system.
Overview
What RMD does
ResMed| (RMD) is a stock in the US Healthcare sector, specifically in the Medical Instruments & Supplies industry. Headquartered in San Diego, United States, the company operates in the digital health and cloud-connected medical devices space. It focuses on sleep and breathing health, offering devices for the diagnosis and treatment of sleep apnea, as well as residential care software. Its products range from portable diagnostic sleep recorders to cloud-based remote monitoring systems and patient therapy management applications.
Key numbers explained
- The current 222.3 USD price is the latest trading value.
- The trailing P/E ratio of 21.3 compares the stock price to the last 12 months of earnings, while the forward P/E ratio of 16.8 uses expected future earnings.
- The dividend yield of 1.19% shows the annual dividend as a percentage of the stock price.
- The beta of 0.77 suggests the stock has historically been less volatile than the overall market.
- The 32.07B USD market capitalization reflects the total market value of all outstanding shares.
- The 10.42 USD earnings per share (trailing 12 months) indicates the portion of profit allocated to each share.
- The 26.9% profit margin shows how much of the 5.65B USD revenue turns into profit.
- The 180.27 – 284.87 52-week price range provides a sense of the stock's recent trading boundaries.
Recent news
Recent headlines highlight ResMed's expected earnings growth, driven in part by increased sleep therapy demand among patients using GLP-1 medications. Analysts have upgraded the stock, citing its leadership in sleep apnea treatment, while other reports examine the potential impact of rising costs on its profit margins.
What to watch
Investors tracking RMD should monitor the company's upcoming earnings report on Oct 29, 2026, and the ex-dividend date of Aug 20, 2026. Broader factors include competitive pressures in the medical devices sector, changes in healthcare policy, and the performance of related companies like Revvity (RVTY) and Charles River Laboratories (CRL). As a component of the S&P 500, its movements can also be influenced by broader market trends.
Latest news & filings
- ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
MarketBeat · Sep 21, 2026
- ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures
Insider Monkey · Sep 19, 2026
- Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
Barrons.com · Sep 15, 2026
- This Analyst Just Upgraded ResMed Stock. Here's Why.
Barchart · Sep 15, 2026
- Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)?
Simply Wall St. · Sep 15, 2026
- ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says
MT Newswires · Sep 15, 2026
- Is This the Right Time to Retain Resmed Stock in Your Portfolio?
Zacks · Sep 15, 2026
- Ulta Beauty, Etsy upgraded: Wall Street's top analyst calls
The Fly · Sep 15, 2026
- Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More
24/7 Wall St. · Sep 15, 2026
- RBC Upgrades ResMed to Outperform From Sector Perform, Raises Price Target to $262 From $244
MT Newswires · Sep 15, 2026
Frequently asked questions
Does RMD pay a dividend?
Yes, ResMed| pays a dividend with a yield of 1.19%. The ex-dividend date is scheduled for Aug 20, 2026, and the company distributes 23% of its earnings as dividends.
What is the RMD P/E ratio?
ResMed| has a trailing P/E ratio of 21.3, based on its last 12 months of earnings. The forward P/E ratio, which uses expected earnings, is 16.8.
Where can I buy RMD?
ResMed| (RMD) is a stock listed on the US market. You can buy it through any brokerage platform that offers access to US stocks, and it is tracked by InvestPane as part of a multi-broker portfolio.
What sector is ResMed in?
ResMed| operates in the Healthcare sector, specifically within the Medical Instruments & Supplies industry.
What is ResMed's market cap?
ResMed| has a market capitalization of 32.07B USD, reflecting its large-cap status in the US market.
Related
More on RMD
Track RMD in your portfolio
Hold RMD at XTB, IBKR, Tradeville, Revolut or Trading 212? InvestPane brings every broker into one dashboard — allocation, performance and dividends in one place.
Start free